• LAST PRICE
    0.4210
  • TODAY'S CHANGE (%)
    Trending Down-0.0100 (-2.3202%)
  • Bid / Lots
    0.4210/ 4
  • Ask / Lots
    0.4400/ 5
  • Open / Previous Close
    0.4350 / 0.4310
  • Day Range
    Low 0.4200
    High 0.4552
  • 52 Week Range
    Low 0.3701
    High 4.7999
  • Volume
    35,135
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 0.431
TimeVolumeDRMA
09:32 ET4170.435
09:37 ET44290.426
09:39 ET2000.425
09:44 ET1000.455243
09:46 ET3000.4316
09:51 ET24720.44
10:02 ET10000.4316
10:24 ET14040.4315
10:26 ET118860.4315
10:27 ET1000.447209
11:07 ET10000.447
11:23 ET21740.42
11:27 ET2500.447
11:43 ET30000.44
11:48 ET2000.4399
12:14 ET2000.4301
12:24 ET10000.4211
12:48 ET20000.4391
12:53 ET2000.4391
01:02 ET5000.44
01:13 ET7000.421
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesDRMA
Dermata Therapeutics Inc
1.6M
-0.1x
---
United StatesGLMD
Galmed Pharmaceuticals Ltd
1.5M
-0.1x
---
United StatesPBLA
Panbela Therapeutics Inc
1.5M
0.0x
---
United StatesADIL
Adial Pharmaceuticals Inc
1.7M
-0.1x
---
United StatesWINT
Windtree Therapeutics Inc
1.7M
0.0x
---
United StatesAMPE
Ampio Pharmaceuticals Inc
1.4M
-0.2x
---
As of 2024-02-22

Company Information

Dermata Therapeutics, Inc. is a clinical-stage medical dermatology company. The Company is focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its product candidates include DMT310 and DMT410. Its lead product candidate DMT310 is intended to utilize its Spongilla technology for the once-weekly treatment of a variety of skin diseases with its initial focus being on the treatment of acne vulgaris. DMT310 completed a Phase Ib proof of concept (POC) trial in psoriasis. Its second product candidate utilizing its Spongilla technology is its combination treatment, DMT410. DMT410 is intended to consist of one treatment of its sponge powder followed by one topical application of botulinum toxin for delivery into the dermis. DMT410 Phase I POC trial of DMT410 for the treatment of multiple aesthetic skin conditions, including reduction of pore size, sebum production, and fine lines.

Contact Information

Headquarters
3525 Del Mar Heights Rd., #322SAN DIEGO, CA, United States 92130
Phone
858-223-0882
Fax
302-636-5454

Executives

Chairman of the Board, President, Chief Executive Officer
Gerald Proehl
Chief Financial Officer, Senior Vice President
Kyri Van Hoose
Senior Vice President - Regulatory Affairs and Quality Assurance
Maria Bedoya Toro Munera
Senior Vice President, Chief Development Officer
Christopher Nardo
Lead Independent Director
David Hale

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$1.6M
Revenue (TTM)
$0.00
Shares Outstanding
3.5M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-5.61
Book Value
$7.82
P/E Ratio
-0.1x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.